Comparing the effects of Oral Contraceptive Pills versus Metformin in the medical management of overweight/obese women with Polycystic Ovary Syndrome
OCPs increase the risk of MetS specifically by producing an atherogenic lipoprotein phenotype, increasing blood pressure and/ or body weight while metformin modestly decreases MetS risk by decreasing body weight and improving lipid phenotype. The combination of OCP and metformin (OCP, through lowering androgens, and metformin, through improvement in insulin sensitivity) will likely decrease the prevalence of MetS, thereby altering the risk profile for the development of diabetes and possible cardiovascular disease (CVD) in young women with PCOS.
- Study Identifier: 827819
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required